Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | BPTF | Q12830 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9445115 | 0.94 | CYP1A2 (0.58) | LMNAHTTCYP1A2BPTFKMT2A | |
| SCHEMBL9198687 | 0.91 | CHRNB2 (0.53) | LMNAHTTCYP1A2BPTFKMT2A | |
| SCHEMBL9200963 | 0.91 | LMNA (0.54) | LMNAHTTCYP1A2BPTFKMT2A | |
| SCHEMBL9218169 | 0.90 | LMNA (0.52) | LMNAHTTCYP1A2BPTFKMT2A | |
| SCHEMBL9196676 | 0.87 | LMNA (0.59) | LMNAHTTCYP1A2BPTFKMT2A | |
| SCHEMBL5884802 | 0.86 | LMNA (0.58) | LMNAHTTCYP1A2BPTFKMT2A | |
| SCHEMBL1562360 | 0.84 | MAPT (0.43) | LMNAHTTCYP1A2BPTFKMT2A | |
| SCHEMBL9194234 | 0.84 | LMNA (0.56) | LMNAHTTCYP1A2BPTFKMT2A | |
| SCHEMBL9198277 | 0.83 | LMNA (0.61) | LMNAHTTCYP1A2BPTFKMT2A | |
| SCHEMBL9216360 | 0.82 | CYP1A2 (0.54) | LMNAHTTCYP1A2BPTFKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1037268-C | Antipicornaviral pyridazinamines | JANSSEM PHARMACEUTICA N V (BE) | 1998-02-04 | — | — | CN | disclosed |
| EP-0435381-B1 | Antipicornaviral pyridazinamines | JANSSEN PHARMACEUTICA NV (BE) | 1995-11-02 | — | — | EP | disclosed |
| EP-0320032-B1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-01-18 | — | — | EP | disclosed |
| EP-0398427-B1 | Antirhinoviral pyridazinamines | JANSSEN PHARMACEUTICA NV (BE) | 1994-03-16 | — | — | EP | disclosed |
| US-5231184-A | Viricide intermediate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-27 | — | — | US | disclosed |
| CN-1021328-C | PROCESS FOR PREPARING PYRIDAZINAMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1993-06-23 | — | — | CN | disclosed |
| US-5196535-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-23 | — | — | US | disclosed |
| US-5106973-A | Viricide intermediates | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-04-21 | — | — | US | disclosed |
| US-5100893-A | Viricides, effective against picorna virus, durability | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-03-31 | — | — | US | disclosed |
| CN-1052857-A | The preparation method of the pyridazine amine that antipicornaviral is used | JANSSEN PHARMACEUTICA NV (BE) | 1991-07-10 | — | — | CN | disclosed |
| EP-0435381-A1 | Antipicornaviral pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-03 | — | — | EP | disclosed |
| US-4992433-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-12 | — | — | US | disclosed |
| EP-0398427-A1 | Antirhinoviral pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-22 | — | — | EP | disclosed |
| EP-0320032-A1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-06-14 | — | — | EP | disclosed |
| CN-1033274-A | The preparation method of new Pyridazinyl amine derivative | JANSSEN PHARMACEUTICA NV (BE) | 1989-06-07 | — | — | CN | disclosed |